Magnetic resonance analysis of malignant transformation in recurrent glioma

Neuro-Oncology

Volumn 18, Issue 8, 2016, Pages 1169-1179

  Jalbert, Llewellyn E ^a   Neill, Evan ^b   Phillips, Joanna J ^a,b   Lupo, Janine M ^b   Olson, Marram P ^b   Molinaro, Annette M ^a,b   Berger, Mitchel S ^a   Chang, Susan M ^a   Nelson, Sarah J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer imaging; Low grade glioma; Magnetic resonance; Malignant transformation; Spectroscopy

Indexed keywords

ISOCITRATE DEHYDROGENASE 1;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BIOINFORMATICS; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; GENE MUTATION; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDH GENE; IN VIVO STUDY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; BRAIN; BRAIN TUMOR; CELL TRANSFORMATION; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM GRADING; YOUNG ADULT;

EID: 84982187318     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now008     Document Type: Article

References (28)

1. Riemenschneider MJ, Reifenberger G. Molecular neuropathology of low-grade gliomas and its clinical impact. Adv Tech Stand Neurosurg. 2010;35(1):35-64
2. Grier JT, Batchelor T. Low-grade gliomas in adults. Oncologist. 2006;11(6):681-693
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773
4. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560-1566
5. Li S, Chou AP, Chen W, et al. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol. 2013;15(1):57
6. Dang L,White DW, Gross S, et al. Cancer-associated IDH1mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744
7. Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015;125(2):296-303
8. Turcan S, Fabius AW, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget. 2013;4(10): 1729-1736
9. Yen KE, Bittinger MA, Su SM, et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010;29(49):6409-6417
10. Park I, Chen AP, Zierhut ML, et al. Implementation of 3T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients. Ann Biomed Eng. 2011;39(1):193-204
11. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson. 1996;111(3):209-219
12. Hartkens T, Rueckert D, Schnabel JA, et al. VTK CISG registration toolkit: an open source software package for affine and non-rigid registration of single-and multimodal 3D images. Leipzig: Springer-Verlag; 2002. http://www.bvm-workshop.org/BVM2002
13. Lee MC, Cha S, Chang SM, et al. Dynamic susceptibility contrast perfusion imaging of radiation effects in normal-appearing brain tissue: changes in the first-pass and recirculation phases. J Magn Reson Imaging. 2005;21(6):683-693
14. Lupo JM, Cha S, Chang SM, et al. Dynamic susceptibility weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. Am J Neuroradiol. 2005;26(6):1446-1454
15. Li Y, Lupo JM, Parvataneni R, et al. Survival analysis in patients with newly diagnosed glioblastoma using pre-and postradiotherapy MR spectroscopic imaging. J Neurooncol. 2013;15(5):607-617
16. Crane JC, Olson MP, Nelson SJ. SIVIC: open-source, standardsbased software for DICOM MR spectroscopy workflows. Int J Biomed Imaging. 2013;2013:169526
17. Elkhaled A, Jalbert LE, Phillips JJ, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4(116):116ra5
18. Elkhaled A, Jalbert L, Constantin A, et al. Characterization of metabolites in infiltrating gliomas using ex vivo 1H highresolution magic angle spinning spectroscopy. NMR Biomed. 2014;27(5):578-593
19. Constantin A, Elkhaled A, Jalbert L, et al. Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. Artif Intell Med. 2012;55(1):61-70
20. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118(5):599-601
21. Lupo JM, Wen Q, Phillips JJ, et al. Weighted-average model curve preprocessing strategy for quantification of DSC perfusion imaging metrics from image-guided tissue samples in patients with brain tumors. Proc Intl Soc Mag Reson Med. 2015;4392
22. Perez-Llamas C, Lopez-Bigas N. Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS ONE. 2011; 6(5):e19541
23. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009
24. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013
25. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504
26. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193
27. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-2508
28. The Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481-2498